Welcome to the sixth issue of the Refractory Asthma Stratification Programme (RASP-UK) newsletter, you can download it now [1].
It was encouraging to see so many partners at the 2017 General Assembly meeting last December, including several new faces from our new partners. Since then, we have seen significant progress across all work-strands which we’ll share with you in this edition. We are now halfway through our third year of the programme. Our Executive Management Team is starting to focus on plans for the reporting of RASP-UK outputs and looking at the legacy we leave behind.
RASP-UK underwent its latest progress review by the MRC on 03 May 2018. As the consortium was judged to be on target in the November 2017 review, we were only required to submit a progress report to the committee. The feedback from the meeting was succinct and positive. The Group thanked the Team for their update and were reassured of the consortium’s progress. In the next report, the Group would appreciate the Team including more description of the patient and public involvement (PPI) activities that the consortium is engaged in. Our next review will be held on 15 Nov 2018 and we hope to have the feedback before the 2018 General Assembly meeting.
The Trial Steering Committee were due to meet on 01 March 2018. However, the meeting was sadly cancelled when storm Emma gripped the UK. Review was completed by email. The committee’s first responsibility was to note with great sadness the untimely death of our patient representative Mark Stafford-Watson, from Southampton. Mark was greatly admired in Southampton and more widely for his tireless engagement in research as an expert patient. The team have sent condolences to Mark’s family. The committee had no safety concerns on our WS1, WS2 or WS3 components and will meet to review again in September 2018.
RASP-UK’s Patient Input Platform continues to ensure that this programme’s studies are patient-centred. Coordinated through Asthma UK, the PIP is formed of seven people affected by severe asthma who have brought a diverse range of experiences to the table and helped to steer focus on the outcomes that matter the most to people with this condition.
The newsletter reported on how the consortium has published one manuscript describing the biomarker studies and three other manuscripts have been submitted to journals and are currently being reviewed.
References
I am shamelessly referencing our Insider’s Insights (IIs) to Dr Who’s TARDIS – our latest edition
The UK's world-class human challenge study gives us new information about SARS-CoV-2 cases that were mild in 36 healthy.
Rational Vaccines (RVx) announces MHRA Innovation Licensing and Access Pathway (ILAP) approval for their live attenuated.
Welcome to the seventh issue of the Refractory Asthma Stratification Programme (RASP-UK) newsletter
The largest pharmaceutical companies not surprisingly rely on the largest contract research organizations
Investigator sites are very important to clinical studies because they make sure that new drugs are safe and work well.
ive years ago I was lucky enough to be involved in a project that resulted in publications
Have you seen our latest Insider's Insight on Case Reports? Once a staple of medical journals,
Advisory board meetings are often used to address perceived knowledge gaps and build consensus.
The proceedings of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI)
Experience at Niche has taught us that clinical study protocols are born in the white-hot fire
Investigator-Initiated Clinical Trials (IITs) are clinical studies led by academic researchers or clinicians
Concerns about readiness of the European Medicines Agency’s (EMA) Clinical Trials Information System persist as the.
Frights create a happy Halloween by providing the thrill of fear in a controlled and safe environment, turning what.
When I was younger, the opening lines of the Beatle’s seminal ‘Sgt. Pepper’s Lonely Hearts Club Band’ resonated.
Every year, a huge amount of scientific data is released. It's out there, but how do you find it?
The clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer,
Get our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
